Tabrecta tablets 150mg, containing Capmatinib hydrochloride hydrate, are manufactured by Novartis Pharma. This medication (YJ code: 4291067F1023, 150mg 1 tablet) is a kinase inhibitor typically used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) exhibiting MET exon 14 skipping.
Tabrecta tablets 150mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).
